Equities research analysts at StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research note issued on Wednesday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Trading Up 8.9 %
Shares of NAVB opened at $0.06 on Wednesday. The stock has a 50-day moving average price of $0.06 and a 200-day moving average price of $0.07. Navidea Biopharmaceuticals has a 12-month low of $0.02 and a 12-month high of $0.35.
Institutional Investors Weigh In On Navidea Biopharmaceuticals
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
- Five stocks we like better than Navidea Biopharmaceuticals
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Lockheed Martin and RTX Corporation: One to buy, one to let fly?
- Best Stocks Under $10.00
- Can Palantir overcome doubts amid triple-digit earnings growth?
- How to Invest in Pharmaceutical Companies
- AI growth propels semiconductor stocks to new highs
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.